BioMarin Pharmaceutical (BMRN) Financial Analysis & Valuation | Quarter Chart
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage... more
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $10.83B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Alexander Hardy |
| IPO Date | 1999-07-26 | CAGR | 33.97% |
| Employees | 3,221 | Website | www.biomarin.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 2.09% | Total Yield | 2.09% |
BMRN chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $12.87B | P/E | 26.9 | Forward P/E | 8.71 | PEG | -1.86 |
| P/S | 0.84 | P/B | 0.45 | P/CF | 2.62 | P/FCF | 3.02 |
| Sales | $3.41B | Sales 1Y | 11.2% | Sales 3Y | 52.45% | Sales 5Y | 77.74% |
| EPS | $2.08 | EPS 1Y | -88.43% | EPS 3Y | -23.96% | EPS 5Y | -90.91% |
| Sales QoQ | 29.17% | EPS QoQ | -57.41% | Sales QoQ Avg | 5.87% | EPS QoQ Avg | -119.59% |
| Gross Margin | 75.55% | Operating Margin | 8.02% | Profit Margin | 2.14% | ROCE | 2.72% |
| ROA | 1% | ROE | 1% | Altman Z Score | 1.74 | Piotroski Score | 4 |
| Current Ratio | 2.39 | Quick Ratio | 1.32 | Cash Ratio | 0.53 | Op. CF Ratio | 0.23 |
| Debt/Equity | 0.66 | Debt/Assets | 0.36 | Lt Debt/Equity | 0.56 | Lt Debt/Cap. | 0.36 |
| Intrst Cov. | -3.75 | Inventory Turnover | 0.47 | Asset Turnover | 0.29 | Receivables Turnover | 3.21 |
| Enterprise Value | $12.87B | P/E Ratio | 26.9 |
| Forward P/E | 8.71 | PEG Ratio | -1.86 |
| P/S Ratio | 0.84 | P/B Ratio | 0.45 |
| P/CF Ratio | 2.62 | P/FCF Ratio | 3.02 |
| EPS | $2.08 | EPS Growth 1Y | -88.43% |
| EPS Growth 3Y | -23.96% | EPS Growth 5Y | -90.91% |
| Revenue Growth 1Y | 11.2% | Gross Margin | 75.55% |
| Operating Margin | 8.02% | Profit Margin | 2.14% |
| ROE | 1% | ROA | 1% |
| ROCE | 2.72% | Current Ratio | 2.39 |
| Quick Ratio | 1.32 | Cash Ratio | 0.53 |
| Debt/Equity | 0.66 | Interest Coverage | -3.75 |
| Altman Z Score | 1.74 | Piotroski Score | 4 |
BioMarin Pharmaceutical (BMRN) valuation & financials
BioMarin Pharmaceutical (BMRN) has a market capitalization of $10.83B and trades at a price-to-earnings ratio of 26.9. It operates in the Healthcare sector (Biotechnology).
BioMarin Pharmaceutical's revenue grew +11.2% over the last year.
BioMarin Pharmaceutical's next earnings report is scheduled for October 26, 2026 (provider scheduled date); analysts estimate EPS of $1.35. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)